Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Diabetic Nephropathies, Proteinuria, Oxidative Stress
Interventions: N-acetylcysteine, silibin, high-dose silibin, N-acetylcysteine placebo, silibin placebo; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Autistic Disorder
Interventions: Methyl B12, Placebo; Drug · Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 3 Years to 7 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Asthma, Allergic Rhinitis
Interventions: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris; Drug
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 6 Years to 15 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Green Tree, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Cavities of Teeth
Interventions: OpalSeal, TransbondXT; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 10 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Burns
Interventions: cNP8, Placebo; Drug · Other
Lead sponsor: Neomatrix Therapeutics, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Femoral Neck Fractures
Interventions: Tranexamic Acid, Placebo (saline); Drug
Lead sponsor: UConn Health; Other
Eligibility: 55 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Farmington, Connecticut • Hartford, Connecticut

Conditions: Depressive Disorder, Major
Interventions: orvepitant, placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Arcadia, California + 14 more

Conditions: Cystic Fibrosis
Interventions: Recombinant Human DNase (Pulmozyme), Placebos; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Month to 30 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Premenstrual Dysphoric Disorder
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • Richmond, Virginia

Conditions: HIV Infections, Fatigue
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Stargardt Disease 1
Interventions: Tinlarebant, Placebo; Drug
Lead sponsor: Belite Bio, Inc; Industry
Eligibility: 12 Years to 20 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Palo Alto, California • Minneapolis, Minnesota • Salt Lake City, Utah

Conditions: Cystic Fibrosis
Interventions: Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Vasodilation, Arterial Stiffness
Interventions: Acetylcholine, Sodium Nitroprusside, Ascorbic Acid; Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: HIV Infections
Interventions: Ad35-ENV vaccine, Ad26.ENVA.01 vaccine, Placebo Control; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autism, Severe Behavior Disorder
Interventions: placebo, glutathione, glutathione, vit C and NAC; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 5 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Breast Cancer
Interventions: Curcumin C3 Complex, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: shark cartilage extract AE-941, placebo, cisplatin, vinorelbine tartrate, carboplatin, paclitaxel, radiation therapy; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: Nitrous oxide 10% & placebo, Nitrous oxide 20% & placebo, Nitrous oxide 30% & placebo, Nitrous oxide 40% and placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 32 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 1997
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions: Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Cypress, California • Glendale, California • Denver, Colorado + 4 more

Conditions: Healthy, Late Onset Pompe Disease
Interventions: ABX1100 injection for IV infusion, Placebo injection for IV infusion; Drug
Lead sponsor: Aro Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Orange, California • St Louis, Missouri • Fairfax, Virginia

Conditions: Bipolar I Disorder, Bipolar II Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 33
States / cities: Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 29 more

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 34
States / cities: Little Rock, Arkansas • Imperial, California • Lemon Grove, California + 29 more

Conditions: Idiopathic Restless Legs Syndrome
Interventions: placebo and pregabalin, pramipexol, Pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 42
States / cities: Birmingham, Alabama • Jasper, Alabama • Tuscaloosa, Alabama + 35 more

Conditions: Renal Dialysis, Vitamin D Deficiency
Interventions: Cholecalciferol (Vitamin D); Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

An Evaluation of Protective Effects of OpalSeal™ Against Early Dental Decay in Orthodontic Patients

Phase 1 Healthy Volunteer Burn Therapy Study

Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder

Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Targeting ER Stress in Vascular Dysfunction

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Role of Instructions in Nitrous Oxide Effects and Choice - 10

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

Vitamin D Supplementation in Kidney Disease